Market Cap | 95.91M | P/E | - | EPS this Y | 54.50% | Ern Qtrly Grth | - |
Income | -95.31M | Forward P/E | -1.20 | EPS next Y | 33.30% | 50D Avg Chg | 5.00% |
Sales | - | PEG | -0.10 | EPS past 5Y | - | 200D Avg Chg | 10.00% |
Dividend | N/A | Price/Book | 1.05 | EPS next 5Y | 15.50% | 52W High Chg | -82.00% |
Recommedations | 1.70 | Quick Ratio | 3.58 | Shares Outstanding | 90.08M | 52W Low Chg | 95.00% |
Insider Own | 3.34% | ROA | -66.80% | Shares Float | 52.16M | Beta | 1.84 |
Inst Own | 62.58% | ROE | -143.47% | Shares Shorted/Prior | 2.35M/2.52M | Price | 2.16 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,094,725 | Target Price | 12.75 |
Oper. Margin | - | Earnings Date | Aug 8 | Volume | 510,613 | Change | -7.30% |
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
EF Hutton | Buy | Sep 18, 24 |
EF Hutton | Buy | Sep 16, 24 |
B. Riley Securities | Buy | Aug 27, 24 |
Piper Sandler | Overweight | Jul 16, 24 |
Brookline Capital | Buy | Apr 5, 24 |
Wedbush | Outperform | Oct 10, 23 |
Wedbush | Outperform | Jul 27, 23 |
SVB Leerink | Market Perform | Oct 21, 22 |
Aegis Capital | Buy | Aug 8, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Whaley Glenn | Chief Financial Offi.. Chief Financial Officer | May 15 | Buy | 1.75 | 5,000 | 8,750 | 25,510 | 05/16/23 |
Neermann Joerg | Director Director | Nov 23 | Buy | 1.39 | 18,000 | 25,020 | 18,000 | 11/25/22 |
Vitt Daniel | President and CEO President and CEO | Nov 22 | Buy | 1.3499 | 8,000 | 10,799 | 376,877 | 11/23/22 |
Whaley Glenn | Chief Financial Offi.. Chief Financial Officer | Nov 07 | Buy | 1.495 | 5,000 | 7,475 | 20,510 | 11/08/22 |
Vitt Daniel | President and CEO President and CEO | Jun 03 | Buy | 3.0999 | 5,000 | 15,500 | 368,877 | 06/06/22 |
Whaley Glenn | Chief Financial Offi.. Chief Financial Officer | Jun 03 | Buy | 3.045 | 3,500 | 10,658 | 12,568 | 06/06/22 |
Muehler Andreas | Chief Medical Office.. Chief Medical Officer | May 12 | Buy | 5.10 | 3,500 | 17,850 | 297,986 | 05/16/22 |